Heart-lung interactions in sepsis

Respiratory-Circulatory Interactions in Health and Disease

Volumn , Issue , 2001, Pages 739-762

  Magder, Sheldon ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882474093     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (102)

1. Ulevitch RJ. Endotoxin opens the Tollgates to innate immunity. Nature Med 1999; 5:144-145.
2. Danner RL, Joiner KA, Parillo JE. Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-Lipid X. J Clin Invest 1987, 80:605-612.
3. Raetz CRH, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991; 5:2652-2660.
4. Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, Matsushima K. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kB and regulation of cytokine production/action through b2 integrin in vivo. J Leukoc Biol 1996; 59:145-151.
5. Ertel W, Kremer J, Kenney J. Down-regulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347.
6. Hensler T, Heidecke CD, Hecker H. Increased susceptibility to postoperative sepsis in patients with imparied monocyte IL-12 production. J Immunol 1998; 161: 2655-2659.
7. Marie C, Muret J, Fitting C. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998; 91:3439-3446.
8. Van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997; 175: 118-122.
9. Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, MacVittie TJ, Walker RI, Parrillo JE. Role of endotoxemia in cardiovascular dysfunction and mortality. J Clin Invest 1989; 83:243-251.
10. Parillo JE. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-242.
11. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477.
12. Rackow EC, Astiz ME. Mechanisms and management of septic shock. Crit Care Clin 1993; 9:219-237.
13. Ziegler EJ. Tumor necrosis factor in humans. N Engl J Med 1988; 318(23):1533-1535.
14. Kurose I, Kubes P, Wolf R, Anderson DC, Paulson J, Miyasaka M, Granger DN. Inhbition of nitric oxide production: mechanisms of vascular albumin leakage. Circ Res 1993; 73:164-171.
15. Kurose I, Wolf R, Grisham MB, Yee Aw T, Specian RD, Granger DN. Microvascular responses to inhibition of nitric oxide production: role of active oxidants. Circ Res 1995; 76:30-39.
16. Busse R, Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990; 265:133-136.
17. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92:1866-1874.
18. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger DM, Stern DM, Waldherr R, Saeger H-D, Ziegler R, Bierhaus A, Martin F, Nawroth PP. Role of NFkB in the mortality of sepsis. J Clin Invest 1997; 100:972-985.
19. Duff JH, Groves AC, McLean APH, LaPointe R, MacLean LD. Defective oxygen consumption in septic shock. Surg Gynecol Obstet 1969; 128:1051-1060.
20. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15:923-929.
21. Wilson RF, Thal AP, Kindling PH, Grifka T, Akerman E. Hemodynamic measurements in septic shock. Arch Surg 1969; 1965:121-129.
22. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100:483-490.
23. Parker MM, Suffredini AF, Natanson C, Ognibene P, Shelhamer JH, Parillo JE. Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 1989; 4:19-25.
24. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. New Engl J Med 1989; 321:280-287.
25. Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parrillo JE. Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93:903-910.
26. Datta P, Magder S. Hemodynamic response to norepinephrine with and without inhibition of nitric oxide synthase in porcine endotoxemia. Am J Respir Crit Care Med. 1999; 160:1987-1993.
27. Fleming I, Julou-Schaeffer G, Gray GA, Parratt JR, Stoclet JC. Evidence that an Larginine/nitric oxide dependent elevation of tissue cyclic GMP content is involved in depression of vascular reactivity by endotoxin. Br J Pharmacol 1991; 103:1047-1052.
28. Gray GA, Schott C, Julou-Schaeffer G, Fleming I, Parratt JR, Stoclet JC. An investigation of the effect of inhibitors of the L-arginine pathway on endotoxin-induced vascular hyporeactivity in vivo. Br J Pharmacol 1991; 103:1218-1224.
29. Gray GA, Schott C, Julou-Schaeffer G, Fleming I, Parratt JR, Stoclet JC. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol 1991; 103:1218-1224.
30. Nava E, Palmer MJ, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 1991; 338:1555-1557.
31. Nava E, Palmer RMJ, Moncada S. The role of ntiric oxide in endotoxic shock: effects of NG- monomethyl-L-arginine. J Cardiovasc Pharmacol 1992; 20:S132-S134.
32. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 1995; 3:2-32.
33. Rastegarpanah M, Magder S. Role of sympathetic pathways in the vascular response to sepsis. J Crit Care 1998; 13:169-176.
34. Yamamoto S, Burman HP, O’Donnell CP, Cahill PA, Robotham JL. Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock. Am J Physiol 1997; 272:H1239-H1249.
35. Suba EA, McKenna TM, Williams TJ. In vivo and in vitro effects of endotoxin on vascular responsiveness to norephinephrine and signal transduction in the rat. Circ Shock 1992; 36:127-133.
36. Farquhar I, Martin CM, Lam C, Potter R, Ellis CG, Sibbald WJ. Decreased capillary density in vivo in bowel mucosa of rats with normotensive sepsis. J Surg Res 1996; 61:190-196.
37. Lam C, Tyml K, Martin C, Sibbald W. Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest. 1994; 94:2077-2083.
38. Brigham KL, Bowers RE, Haynes J. Increased sheep lung vascular permeability caused by Escherichia coli endotoxin. Circ Res 1979; 45:292-297.
39. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992; 31:H611-H615.
40. Sessler CN, Bloomfield GL, Fowler AA. Current concepts of sepsis and acute lung injury. Clin Chest Med 1996; 17:213-235.
41. Owada A, Tomita K, Terada Y, Sakamoto H, Nonoguchi H, Marumo F. Endothelin (ET)-3 stimulates cyclic guanosine 3′,5′-monophosphate production via ETB receptor by producing nitric oxide in isolated rat glomerulus, and in cultured rat mesangial cells. J Clin Invest 1994; 93:556-563.
42. Sugiura M, Inagami T, Kon V. Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun 1989; 161(3):1220-1227.
43. Voerman HJ, Stehouwer CDA, van Kamp GJ, Strack van Schijndel RJM. Groeneveld ABJ, Thijs LG. Plasma endothelin levels are increased during septic shock. Crit Care Med. 1992; 20:1097-1101.
44. Shoemaker WC, Appel PL, Bishop MH. Temporal patterns of blood volume, hemodynamics, and oxygen transport in pathogenesis and therapy of postoperative adult respiratory distress syndrome. New Horiz 1993; 1:522-537.
45. Parillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1477.
46. Schwartz DR, Malhotra A, Fink MP. Cytopathic hypoxia in sepsis: an overview. Sepsis 1998; 2:279-289.
47. Hussain SNA, Abdul-Hussain MN, El-Dwairi Q. Exhaled nitric oxide as a marker for serum nitric oxide concentration in acute endotoxemia. J Crit Care 1996; 11: 167-175.
48. Hussain SNA, Graham R, Rutledge F, Roussos C. Respiratory muscle energetics during endotoxic shock in dogs. J Appl Physiol 1986; 60:486-493.
49. Bates DV. Syndromes of respiratory failure. In:Respiratory Function in Disease, edited by D.V. Bates. Philadelphia: W.B. Saunders Company, 1989, p. 382-386.
50. Marini JJ. Lung mechanics in the adult respiratory distress syndrome. Clin Chest Med 1990; 11:673-690.
51. Hussain SNA, Simkus G, Roussos C. Respiratory muscle fatigue: a cause of ventilatory failure in septic shock. J Appl Physiol 1985; 58:2033-2040.
52. Reemtsma K, Hottinger GC, Degraff AC, Jr, Creech O Jr. The estimation of hepatic blood flow using indocyanine green. Surg Gynecol Obstet 1960; 3:353-356.
53. Rothe CF. Reflex control of veins and vascular capacitance. Physiol Rev 1983; 63(4):1281-1295.
54. Magder S, De Varennes B. Clinical death and the measurement of stressed vascular volume. Crit Care Med 1998; 26:1061-1064.
55. Hermreck AS, Thal AP. Mechanisms for the high circulatory requirements in sepsis and septic shock. Ann Surg 1969; 170:677-695.
56. Magder S, Vanelli G. Circuit factors in the high cardiac output of sepsis. J Crit Care 1996; 111:155-166.
57. Magder S, Quinn R. Endotoxin and the mechanical properties of the canine peripheral circulation. J Crit Care 1991; 6:81-88.
58. Caldini P, Permutt S, Waddell JA, Riley RL. Effect of epinephrine on pressure, flow, and volume relationships in the systemic circulation of dogs. Circ Res 1974; 34:606-623.
59. Notarius CF, Levy RD, Tully A, Fitchett D, Magder S. Cardiac vs. noncardiac limits to exercise following heart transplantation. Am Heart J 1998; 135: 339-348.
60. Magder S, Javeshghani D, Cernacek P, Giaid A. Differential expression of endothelin in endotoxic pigs-a possible hormonal role. Am J Respir Crit Care Med 1997; 155(4):A930.
61. Deschamps A, Magder S. Effects of heat stress on vascular capacitance. Am J Physiol 1994; 266:H2122-H2129.
62. Green JF. Mechanism of action of isoproterenol on venous return. Am J Physiol 1977; 232(2):H152-H156.
63. Guyton AC, Jones CE, Coleman TG. Circulatory Physiology: Cardiac Output and Its Regulation. Philadelphia: W.B. Saunders, 1973.
64. Taveira da Silva AM, Kaulbach FS, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of salmonella endotoxin. N Engl J Med 1993; 328:1457-1460.
65. Atherton JJ, Moore TD, Lele SS, Thomson HL, Galbrath AJ, Belenkie I, Tyberg JV, Frenneaux MP. Diastolic ventricular interaction in chronic heart failure. Lancet 1997; 349:1720-1724.
66. Atherton JJ, Thomson HL, Moore TD, Wright KN, Muehle GWF, Fitzpatrick LE, Frenneaux MP. Diastolic ventricular interaction. A possible mechanism for abnormal vascular responses during volume unloading in heart failure. Circulation 1997; 96:4273-4279.
67. Mitzner W. Resistance of pulmonary circulation. Clin Chest Med 1983; 4(2):127-137.
68. Parillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76:1539-1553.
69. Parker MM, McCarthy KE, Ognibene FP, Parillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97:126-131.
70. Brealey D, Singer M. Tissue oxygenation in sepsis. Sepsis 1998; 2:291-302.
71. Hussain S, Chatillon A, Comtois A, Roussos C, Magder S. The chemical activation of thin-fiber phrenic afferents: cardiovascular responses. J Appl Physiol 1991; 70:77-86.
72. Hussain SNA, Magder S. Respiratory muscle function in shock and infection. Semin in Respir Med 1991; 12:287-297.
73. Hussain SNA, Roussos C. Distribution of respiratory muscle and organ blood flow during endotoxic shock in dogs. J Appl Physiol 1985; 59:1802-1808.
74. Boczkowski J, Dureuil B, Brauger C, Aubier, M. Effects of sepsis on diaphragmatic function in rats. Am Rev Resp Dis 138, 260-265. 1988. (GENERIC) Ref Type: Journal (Full).
75. Hussain SNA, Chatillon A, Comtois A, Roussos C, Magder S. Chemical activation of thinfiber phrenic afferents. 2. The cardiovascular responses. J Appl Physiol 1991; 70:159-167.
76. Teitelbaum J, Borel CO, Magder S, Traystman RJ, and Hussain SNA. Effect of selective diaphragmatic paralysis on the inspiratory motor drive. J Appl Physiol 1993; 74:2261-2268.
77. Teitelbaum JS, Magder SA, Roussos C, Hussain SNA. Effects of diaphragmatic ischemia on the inspiratory motor drive. J Appl Physiol 1992; 72:447-454.
78. Walker G, Pfeilschifter J, Kunz D. Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-y-stimulated RAW 264.7 cells by dexamethasone. J Biol Chem 1996; 271:16679-16687.
79. Deschamps A, Magder S. Baroreflex control of regional capacitance and blood flow distribution with or without alpha adrenergic blockade. J Appl Physiol 1992;1263:H1755-H1763.
80. Appleton C, Olajos M, Morkin E, Goldman S. Alpha-1 adrenergic control of the venous circulation in intact dogs. J Pharmacol Exp Ther 1985; 233:729-734.
81. Wenzel RP. Anti-endotoxin monoclonal antibodies-a second look. N Engl J Med 1992; 326:1151-1153.
82. Desjars P, Pinaud M, Bugnon D, Tasseau F. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989; 17:426.
83. Schaer GL, Fink MP, Parrillo JE. Norepinephrine alone versus norepinephrine plus lowdose dopamine: Enhanced renal blood flow with combination pressor therapy. Crit Care Med 1985; 13:492-496.
84. Goldberg LI. Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 1972; 24:1-29.
85. Hannemann L, Reinhart K, Grenzer O, Meier-Hellmann A, Bredle DL. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995; 23:1962-1970.
86. Kilbourn RG, Cromeens DM, Chelley FD, Griffith OW. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemia dogs. Crit Care Med 1994; 22:1835-1839.
87. Ruffolo RR Jr. Messick K. Effects of dopamine, (+)-dobutamine and the (+) and (+)- enantiomers of dobutamine on cardiac function in pithed rats. J Pharmacol Exp Ther 1985; 235:558-565.
88. Vincent JL, Van der Linden P, Domb M, Bleic S, Azimi G, Bernard A. Dopamine compared with dobutamine in experimental septic shock: relevance of fluid administration. Anesth Analg 1987; 66:565-571.
89. MacLean LD, Mulligan WG, McLean APH, Duff JH. Patterns of septic shock in man-A detailed study of 56 patients. Ann Surg 1967; 166:543-562.
90. Kilbourn R, Gross S, Jubran A, Adams J, Griffith O, Levi R, Lodata R. NG-methyl-Larginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA. 1990; 87:3629-3632.
91. Pastor C, Teisseire B, Vicaut E, Payen D. Effects of L-arginine and L-nitroarginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 1994; 22:465-469.
92. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338:1557-1558.
93. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182:591-595.
94. Hom GJ, Grant SK, Wolfe G, Bach TJ, MacIntyre DE, Hutchinson NI. Lipopolysaccharideinduced hypotensiona nd vascular hyporeactivity in the rat: Tissue analysis of nitric oxide synthase mRNA and protein expression in the presence and absence of dexamethason, N00G-monomethyl-L-arginine or indomethacin. JPET 1995; 272:452-459.
95. Petros AJ, Hewlett AM, Bogle RG, Pearson JD. L-arginine-induced hypotension. Lancet 1991; 337:1044-1045.
96. Mehta S, Javeshghani D, Datta P, Levy RD, Magder S. Porcine endotoxaemic shock is associated with increased expired nitric oxide. Crit Care Med 1999; 27:385-393.
97. Magder S, Kabsele K. Evidence for constitutive release of nitric oxide in the venous circuit of pigs. J Cardiovasc Pharmacol 1998; 32:366-372.
98. Chollet-Martin C, Gatecel C, Keermarrec N, Gougerot-Posicalo MA, Payen D. Alveolar neutrophil functions and cytokine levels during nitric oxide inhalation in ARDS patients. Am J Respir Crit Care Med 1996; 153:985-990.
99. Amata MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347-354.
100. Pinksy MR, Summer WR, Wise RA, Permutt S, Bromberger-Barnea B. Augmentation of cardiac function by elevation of intrathoracic pressure. J Appl Physiol Respir Environ Exercise Physiol 1983; 54:950-955.
101. Aubier M, Trippenbach T, Roussos C. Respiratory muscle fatigue during cardiogenic shock. J of Appl Physiol Respir, Environ Exericse Physiol 1981; 51:499-508.
102. Viires N, Sillye G, Aubier M, Rassidakis A, Roussos C. Regional blood flow distribution in dog during induced hypotension and low cardiac output. Spontaneous breathing versus artificial ventilation. J Clin Invest 1983; 72:935-947.